About us


Alvogen is built on the strong foundation of Norwich Pharmaceutical Services, an U.S. company with over 130-year history. With a fully integrated brand and generics business, the U.S. market is Alvogen’s single largest market. The company is fast growing with a well targeted generics and brand portfolios, as well as commercial and product development infrastructure and pharmaceutical contract services.

Alvogen has commercial operations in 35 countries with 2,800 employees and operates five manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter brands (OTC’s) and biosimilar products for patients around the world.


Pipeline ANDA'S

Meet management


Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Meet management

Lines of business

Alvogen business in the U.S. is categorized into two major focus areas; generic pharmaceuticals and sales of third party services, such as contract manufacturing, pilot plant contract development and clinical research.

Third party contract manufacturing and development services are provided by the Company's manufacturing facility in Norwich located in New York State under the Norwich Pharmaceuticals brand.


Alvogen has commercial operations in more 35 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.

Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Connect with local teams to learn more about product offering in your region.

World offices